The future of anticoagulation clinics

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Novel antithrombotic agents are emerging, potentially impacting anticoagulation services.
• Oral direct thrombin inhibitors, such as ximelagatran, offer improved convenience over warfarin.
• Current anticoagulation clinics provide systematic warfarin management, improving patient outcomes.

Purpose of the Study:

• To assess the potential impact of novel antithrombotic agents, specifically ximelagatran, on anticoagulation clinics.
• To explore how anticoagulation clinics may need to adapt their services in response to new therapies.
• To examine the potential shift towards comprehensive antithrombotic disease management.

Main Methods:

• Review of current literature on novel antithrombotic agents and their clinical investigations.
• Analysis of the established role and outcomes of anticoagulation clinics in managing warfarin therapy.
• Projection of future service models for anticoagulation clinics facing the integration of new agents.

Main Results:

• Ximelagatran shows promise for oral anticoagulation management due to ease of use compared to warfarin.
• Ximelagatran is under investigation for indications including VTE prophylaxis, VTE treatment, stroke prevention in AF, and ACS.
• The introduction of ximelagatran is expected to alter workload dynamics in anticoagulation clinics.

Conclusions:

• Anticoagulation clinics must evolve from warfarin monitoring to managing thrombotic diseases and coordinating all antithrombotic therapies.
• Survival of anticoagulation clinics depends on adapting to novel agents and broadening service scope.
• Comprehensive Antithrombosis Centers (CAC) are likely to emerge as key providers for patients on diverse anticoagulant therapies.